stockrow908 Devices Inc.
MASS Healthcare Medical Devices
908 Devices Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.2 million, up 17.7% from fiscal 2024.
- Revenue
- +23.3%
- EPS
- +13.5%
- Free cash flow
- +151.0%
Quarter to June 2026, against a year earlier
Follow MASS
Alert me
908 Devices Inc. (MASS) EV/Sales
As of 5 November 2026, 908 Devices Inc. (MASS) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from 0.2× (December 2024) to 48.2× (April 2021); the current reading is higher than 66% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | 258.89% |
| FY2024 | 0.5× | (88.05%) |
| FY2023 | 3.8× | 203.72% |
| FY2022 | 1.2× | (89.81%) |
| FY2021 | 12.2× | 30.69% |
| FY2020 | 9.3× | 11.39% |
| FY2019 | 8.4× | 0.00% |
| FY2018 | 8.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.0× | 78.25% |
| Mar 2026 | 2.2× | 37.92% |
| Dec 2025 | 1.6× | (60.82%) |
| Sep 2025 | 4.1× | 45.24% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CERS Cerus Corporation compare | 1.7× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.4× |
| NPCE NeuroPace, Inc. compare | 4.5× |
| DCTH Delcath Systems, Inc. compare | 4.5× |
| MASS 908 Devices Inc. | 4.9× |
| SI Shoulder Innovations, Inc. compare | 5.4× |
| RCEL Avita Medical Inc. compare | 6.7× |
| SSII SS Innovations International, Inc. compare | 7.1× |
| SENS Senseonics Holdings, Inc. compare | 8.3× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)